July 25, 2025 16:05 ET | Source: Celcuity Inc. MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC),…
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused…
11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in…
From Mumbai to the world—experience education through a dual-campus global management programme MUMBAI, India, June 5, 2025 /PRNewswire/ -- Bharatiya Vidya Bhavan's…